Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Breast Neoplasms 18Triple Negative Breast Neoplasms 3Sarcoma 2Neoplasm Metastasis 2Refractory Solid Tumors 1Metastatic HER2-positive Breast Cancer 1Melanoma 1Inoperable Locally Advanced HER2-Negative Breast Cancer 1HER2-negative Breast Cancer 1HER2-low Breast Cancer 1Fludzoparib" and Anti-angiogenic 1Diabetes Mellitus, Insulin-Dependent, 12 1Colorectal Neoplasms 1Carcinoma, Renal Cell 1Carcinoma, Hepatocellular 1Brain Neoplasms 1Advanced Breast Cancer 1

Interventions

eribulin 1Temozolomide 1Irinotecan 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Refractory Solid Tumors × eribulin × Clear all
NCT06006273 2026-05-20

A Phase Ib Trial of Eribulin in Combination With Irinotecan and Temozolamide in Children With Relapsed or Refractory Solid Tumors

M.D. Anderson Cancer Center

Phase 1 Recruiting
48 enrolled
Other solid neoplasm

Refractory Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡